https://www.facebook.com/454567445300132/

Maine Coon Kittens, Vail, AZ (2024)

11/15/2024

Fat bellies and tiny paws

11/13/2024

Fat and sleepy

11/12/2024

One week old and thriving

11/07/2024

2 dark babies are female, 2 orange/creme babies are male

11/02/2024

Kittens are coming soon!

06/13/2024

The development of a cat allergy vaccine is making significant progress. Angany, a French-Canadian pharmaceutical company, has initiated the first human clinical trial for its vaccine candidate ANG-101. This trial, conducted at the Royal Brompton Hospital in London, received approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) in October 2023 (ANGANY) (euronews).
ANG-101 is a therapeutic vaccine that employs Angany's proprietary eBioparticle-Potentiated Immunotherapy technology. The vaccine aims to provide a disease-modifying approach to treating cat allergies by mimicking a virus in shape and size, with its surface covered by cat major allergen Fel d 1 (Clinical Trials Arena). This approach is designed to induce a strong immune response, potentially offering a more effective and shorter treatment course compared to traditional desensitization methods (The Daily Scan).
The clinical trial will evaluate the safety, allergenicity, and immunogenicity of ANG-101 in adult patients allergic to cat dander. This study represents a significant step towards potentially offering a more efficient and reliable treatment for cat allergies, which currently lack a cure (ANGANY) (Clinical Trials Arena).
The development of a cat allergy vaccine is making significant progress. Angany, a French-Canadian pharmaceutical company, has initiated the first human clinical trial for its vaccine candidate ANG-101. This trial, conducted at the Royal Brompton Hospital in London, received approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) in October 2023 (ANGANY) (euronews).
ANG-101 is a therapeutic vaccine that employs Angany's proprietary eBioparticle-Potentiated Immunotherapy technology. The vaccine aims to provide a disease-modifying approach to treating cat allergies by mimicking a virus in shape and size, with its surface covered by cat major allergen Fel d 1 (Clinical Trials Arena). This approach is designed to induce a strong immune response, potentially offering a more effective and shorter treatment course compared to traditional desensitization methods (The Daily Scan).
The clinical trial will evaluate the safety, allergenicity, and immunogenicity of ANG-101 in adult patients allergic to cat dander. This study represents a significant step towards potentially offering a more efficient and reliable treatment for cat allergies, which currently lack a cure (ANGANY) (Clinical Trials Arena).

Send a message to learn more